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Collectively, lung diseases are one of the largest causes of premature death worldwide and represent a major
focus in the field of regenerative medicine. Despite significant progress, only few stem cell platforms are
currently available for cell-based therapy, disease modeling, and drug screening in the context of pulmonary
disorders. Human foregut stem cells (hFSCs) represent an advantageous progenitor cell type that can be used to
amplify large quantities of cells for regenerative medicine applications and can be derived from any human
pluripotent stem cell line. Here, we further demonstrate the application of hFSCs by generating a near ho-
mogeneous population of early pulmonary endoderm cells coexpressing NKX2.1 and FOXP2. These progen-
itors are then able to form cells that are representative of distal airway epithelium that express NKX2.1,
GATA6, and cystic fibrosis transmembrane conductance regulator (CFTR) and secrete SFTPC. This culture
system can be applied to hFSCs carrying the CFTR mutation Df508, enabling the development of an in vitro
model for cystic fibrosis. This platform is compatible with drug screening and functional validations of small
molecules, which can reverse the phenotype associated with CFTR mutation. This is the first demonstration that
multipotent endoderm stem cells can differentiate not only into both liver and pancreatic cells but also into lung
endoderm. Furthermore, our study establishes a new approach for the generation of functional lung cells that
can be used for disease modeling as well as for drug screening and the study of lung development.
Introduction
Lung disorders are a leading cause of death worldwide,second only to cardiovascular disease. Multiple cell
types participate in the disease pathogenesis, including epi-
thelial cells, myofibroblasts, and cells of the immune system.
However, respiratory epithelial cells (RECs) play the most
pivotal role in coordinating the complex cellular interactions
leading to disease [1]. Indeed, the pulmonary epithelium
shows a unique potential for controlling lung repair, re-
modeling, and fibrosis through epithelial–mesenchymal in-
teractions and orchestrating inflammatory responses through
secretion of pro-inflammatory cytokines [1,2]. Furthermore,
the role of RECs as the interface between the respiratory
tissue and the external environment renders them a prime
target for inhaled therapeutic agents [1]. Therefore, the de-
velopment of robust platforms for studying the respiratory
epithelium could advance our insight into the mechanisms
underlying pulmonary diseases and contribute toward the
generation of novel therapeutic agents. Nevertheless, existing
in vivo models are limited by intra-species variability, while
a long-term primary RECs culture is complicated by tech-
nical challenges and poor access to primary tissue.
The technology of human-induced pluripotent stem cells
(hIPSCs) has contributed toward addressing this challenge
through the development of protocols for the generation of
RECs in vitro [3,4]. However, these existing systems are
limited by significant variability in differentiation capacity
among lines, as well as by an inability to produce sufficiently
pure populations of cell sub-types without genetic manipula-
tion [5]. Ultimately, this limits their overall efficiency and
makes the derivation of large cohorts of patient-specific RECs
problematic. We recently developed a platform for the gen-
eration of human foregut stem cells (hFSCs), with the po-
tential for overcoming such issues [6]. hFSCs resemble
foregut progenitor cells from which multiple endodermal or-
gans originate, including the liver, pancreas, thyroid, thymus,
and lungs [7]. These multipotent stem cells can be derived
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from any human embryonic stem cell (hESC) or hIPSC with a
high efficiency. Furthermore, they can self-renew in vitro for a
prolonged period of time and maintain their capacity to dif-
ferentiate into endoderm lineages, such as the liver and pan-
creatic cells [6]. However, differentiation of hFSCs into RECs
that could overcome issues associated with poor efficiency
and variability between lines has not yet been demonstrated.
In the mouse, foregut specification into lung bud is marked
by the expression of the transcription factors NKX2.1 and
FOXP2 [8], while thyroid progenitors also express NKX2.1
but in combination with PAX8 and HHEX [9,10]. Airway
epithelium differentiates from NKX2.1/FOXP2 progenitors
into secretory Clara cells, neuroendocrine cells, mucus-
producing goblet cells, and ciliated cells (See Table 1 for
summary of lineage markers used for this study). At the
distal tip of the lung, two types of cells are also produced: the
alveolar epithelial cells (AECs) Type I (AECTI) and Type II
(AECTII). In the mature lung, AECTI cells are responsible
for gas exchange and express a variety of markers such as
NKX2.1, GATA6, and the cystic fibrosis transmembrane
conductance regulator (CFTR) [11,12]. The AECTII, which
itself gives rise to the AECTI, also expresses NKX2.1,
GATA6, and CFTR as well as the surfactant proteins that
reduce the alveolar surface tension. While the mature distal
lung epithelium expresses some markers in common with the
embryonic lung bud (NKX2.1, GATA6), coexpression of
functional markers (SFTPB, SFTPC, ABCA3, and AQP5)
enables distinction between these two populations in vitro.
Here, we extend our previous study by showing that fi-
broblast growth factor (FGF)10 combined with retinoic acid
(RA) drives differentiation of hFSCs into cells representative
of the lung bud, which can then produce cells with a profile
similar to the AECTI and AECTII-like cells of the distal
airways. The resulting AEC-like cells display characteristics
of their in vivo counterparts such as NKX2.1 and GATA6
gene expression, as well as functional characteristics such as
surfactant secretion and CFTR activity. We demonstrate the
clinical relevance of our system by using hFSCs derived from
patients with cystic fibrosis (CF) to model key aspects of CF-
associated lung disease in vitro, including defective chloride
transport across the cell membrane. Furthermore, we validate
the importance of our cells as a drug screening system by
reproducing the effects of VX809, a small-molecule com-
pound restoring CFTR function, currently in phase II clinical
trials. Considered together, these results demonstrate the po-
tential of hFSCs as a novel and highly efficient platform for
the generation of distal RECs, with diverse clinical applica-
tions toward studying lung development, modeling respiratory
disease in vitro, and validating novel therapeutic compounds.
Materials and Methods
Generation of hIPSCs
hIPSCs (BBHX8, A1TATD) were derived using retrovirus-
mediated reprogramming of human skin fibroblasts using the
Yamanaka factors. 508CFTR-1, 508CFTR-2 were derived
Table 1. Genes Commonly Expressed in the Lung and Endoderm Lineage
Gene Function Associated cell type(s)
NKX2.1 Transcription factor Lung bud/distal airway/thyroid
FOXP2 Transcription factor Lung bud endoderm
HHEX Transcription factor Thyroid/liver endoderm
GATA6 Transcription factor Lung bud endoderm/distal Lung
IRX1 Transcription factor Lung endoderm
FOXA2 Transcription factor Lung endoderm
PAX8 Transcription factor Thyroid endoderm
PAX9 Transcription factor Thyroid endoderm
FOXJ1 Transcription factor Mature ciliated lung endoderm
SOX17 Transcription factor Mature ciliated lung endoderm
MUC5AC Extracellular glycoprotein Mature upper airway goblet cells
SFTPC Secreted protein Mature distal airway type II
ABCA3 Membrane bound transporter Mature distal airway type II
CFTR Transmembrane channel Mature distal airway type II
MUC1 Extracellular glycoprotein Mature distal airway type II
SFTPB Secreted protein Mature distal airway type II
SFTPC Secreted protein Mature distal airway type II
AQP5 Transmembrane channel Mature distal airway type I
PDPN Transmembrane protein Mature distal airway type I/kidney podocytes
P2X7 Receptor Mature distal airway type I/macrophages/CNS
PAX6 Transcription factor Forebrain
TG Secreted protein Thyroid
CK18 Cytoskeletal protein Epithelium
CD26 Cell surface protein Lungs/kidneys
ZO1 Tight junction protein Epithelium
SOX2 Transcription factor Oesophagus/pluripotency
NANOG Transcription factor Pluripotency
POU5F1 Transcription factor Pluripotency
TRA-1-60 Cell surface protein Pluripotency
Several cell subtypes within the lung express unique markers. The most common markers included in this study, along with their function
and most commonly associated cell type, are included.
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using sendi virus-mediated reprogramming using the Yama-
naka factors.
Maintenance of hESCs and hIPSCs
hESCs (H9) and hIPSCs (BBHX8, A1ATD-1, 508CFTR-1,
508CFTR-2) were cultured in a chemically defined, feeder-
free culture system as previously described using Activin-A
(10 ng/mL) and basic fibroblast growth factor (bFGF)
(12 ng/mL). Cells were passaged every 7 days using colla-
genase for hESCs or a mixture of dispase and collagenase at
a ratio of 1:1 for hIPSCs [6,13].
Differentiation of hIPSCs and hESCs into endoderm
Pluripotent cells that were either hESCs or hIPSCs were
differentiated into definitive endoderm using CDM-PVA
and Activin-A (100 ng/mL), bone morphogenetic protein
(BMP)4 (10 ng/mL), bFGF (20 ng/mL), and LY294002
(10 mM) for 3 days as previously described [6,13]. For
hIPSC differentiation, cells were treated on day 1 of differ-
entiation with CHIR 99021 (10mM) for 24 h. CHIR 99021
was omitted during day 2 and 3 of endoderm differentiation.
A complete protocol has been previously published [6,13].
Patterning of definitive endoderm
After differentiation into definitive endoderm, cells were cul-
tured inRPMI+B27mediumwithActivin-A (50ng/mL) for 3–4
days to generate foregut cells. Foregut cells could be expanded
over time and stably expressed foregut markers, including
SOX17, HNF4a, and GATA4 as previously described [6].
Differentiation of foregut endoderm
to lung epithelium
Foregut endoderm was cultured in RPMI medium con-
taining FGF10 (100 ng/mL) and RA (1 mM) for 4–6 days to
produce a population of NKX2.1/FOXP2-positive HHEX-
negative cells. Cells were then cultured in RPMI medium
containing FGF10 (100 ng/mL) and hepatocyte growth fac-
tor (HGF, 50 ng/mL) for a further 10 days. Cells were then
matured for at least 15 more days in RPMI medium con-
taining FGF10 (100 ng/mL).
Fetal and adult primary tissue samples
Quantitative polymerase chain reaction (QPCR) was per-
formed using human primary fetal lung (FL) control and an
adult distal airway epithelium control. The FL control is rep-
resentative of both lobes of a 7.5 week fetal sample, while the
adult sample is representative of RNA from the lower left lobe
of a healthy male donor (AMSBIO). The hIPSCs used in our
studies were derived from fibroblasts obtained from the Coriell
depository (CF) or obtained from informed patients using the
full ethical approval 08/H0331/201. The hESCs were obtained
from WiCell and were used under the United Kingdom stem
cells steering approval SCSC10-44. Human fetal tissues were
obtained under the ethical approval 13/NW/0205.
RNA isolation, reverse transcription, and QPCR
RNA was isolated using either the GenElute (Sigma-
Aldrich) mammalian total RNA isolation kit or RNeasy Kit
(Qiagen). Cells were washed with phosphate-buffered saline
(PBS) and then lysed in 350mL of RNA lysis buffer. RNA
was purified as per the manufacturer’s instructions. DNA
digestion was performed using RNAase-free DNase (Sigma)
as per the manufacturer’s recommendations. Five hundred
nanogram of total RNA was reverse transcribed using
500 ng total RNA, 0.5 mL random primers (Promega), and
1 mL of dNTP’s (Promega) per reaction. Samples were he-
ated to 65C for 5min and then placed on ice for a further
5min. Four microliter of first-strand buffer (Invitrogen) + 2
mL dithiothreitol (Invitrogen) + 1 mL RNAse OUT (Invitro-
gen) + 0.5 mL SuperScript II (Invitrogen) was added to each
sample and incubated at room temperature for 10min, fol-
lowed by 42C for 75min and 70C for 15min. cDNA was
diluted into a total volume of 500 mL of RNAse-free water.
Five microliter of cDNA per reaction was combined with
7.5 mL Cyber-Green Sensi mix (Bioline), 0.6 mL each of
forward primer and reverse primers, and 1.3 mL of RNAse-
free water. PCR was performed using a Stratagene Ther-
mocycler by using one cycle at 95C for 10min, then 40
cycles of 95C for 30 s, 60C for 30 s, and 72C for 30 s
followed by one cycle at 95C for 1min. All QPCR data
show an average of three experiments, and error bars rep-
resent standard error of the mean. hESCs (H9) were used as
a negative control in all the experiments, and the internal
reference gene used for all QPCR was hydroxymethylbilane
synthase. Statistical analysis was performed using the
GraphPad Prism Software version 6, and all statistical sig-
nificance was calculated using a standard one-way analysis
of variance. Levels of significance are represented as
*P £ 0.05, **P£ 0.01, ***P£ 0.001, and ****P£ 0.0001.
Immunocytochemistry
Cells were fixed for 20min at 4C in 4% paraformalde-
hyde and washed in PBS. Cells were incubated for 20min
at room temperature in phosphate buffered saline Triton
(PBST) (0.1% Triton X-100; Sigma; in PBS) containing
10% donkey serum (Serotec Ltd.) and incubated overnight
at 4C with primary antibody diluted in 1% donkey serum in
PBST. Cells were then washed in PBS and incubated with
secondary antibodies for 2 h at room temperature. Hoechst
33258 was used to visualize DNA. See Supplementary
Table S1 (Supplementary Data are available online at
www.liebertpub.com/scd) for a complete list of primary
antibodies used in this study. Samples were imaged using a
Zeiss Imager M.2, equipped with AxioCam MRm and MRc
cameras and AxioVision software for image capture and
scale bars = 100mM.
Flow cytometry
For a complete list of primary and secondary antibodies
used for flow cytometry, please refer Supplementary Table
S1. Adherent cells were washed twice in PBS and then
incubated for 20min at 37C in cell dissociation buffer
(Invitrogen). Cells were dissociated by gentle pipetting and
resuspended at *0.1–1 · 106 cells/mL in PBS. For live cell
surface staining, cells were blocked for 30min using 10%
donkey serum before staining. For internal markers, cells
were pelleted and fixed by resuspending cells in 4% para-
formaldehyde solution at 4C for 20min. Cells were washed
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in PBS, then blocked, and permeabilized in PBS containing
10% donkey serum and 0.01% Triton X-100. Cells were
incubated in 1% donkey serum 0.001% Triton X-100 con-
taining the primary antibody overnight at 4C. Cells were
then washed in PBS 1% donkey serum and incubated with
secondary antibodies overnight at 4C. Cells were analyzed
using an FACS Calibur machine (BD Biosciences). All flow
cytometry experiments were gated first using unstained cells
and then cells containing the secondary antibody only. On all
flow cytometry plots, the secondary-only population is
shown in gray. All gates shown on scatter and histogram
plots were set to the secondary only control. All flow cy-
tometry was validated with immunocytchemistry to ensure
false-positive or -negative results were not recorded.
CFTR assay
Lung epithelial cells were transferred to 35mm glass-
bottom tissue culture dishes 5 days before the CFTR assay.
Wild-type and CFTR mutant hPSCs were treated with or
without the small molecules VX809 for 48 h (30mM) before
the commencement of the assay or transferred to an incu-
bator at 28C 6h before the beginning of the assay. Cells
were then loaded with the chloride-sensitive dye [N-
(ethoxycarbonylmethyl)-6-methoxyquinolinium bromine]
(MQAE) (Life Technologies) for 4 h before performing the
assay. Ringer’s solution was made to measure chloride in-
flux. Standard Ringers solution consisting of 140mM NaCl,
5mM KCl, 1.5mM CaCl, 1mM MgCl, 10mM glucose, and
4mM HEPES was used as the chloride positive solution. To
measure chloride efflux, Ringers solution was made as de-
scribed earlier by exchanging Cl for NO3, 140mM NaNO3,
5mM KNO3, 1.5mM CaNO3, 1mM MgNO3, 10mM glu-
cose, and 4mM HEPES. A perfusion insert was then placed
inside the 35mm organ culture plates containing lung epi-
thelial cells loaded with MQAE (8mM). A vacuum pump
was attached to the outlet manifold, and Ringers solution
was injected through the inlet port. Images were captured on
an inverted microscope measuring fluorescent acitivity at an
excitation wavelength of 370 nm and an emission at 450 nm.
Live images were captured at a rate of four frames per
second, and different solutions were added. A CFTR in-
hibitor (CFTR-172; Sigma; 10 mM) was added to demon-
strate specificity to the CFTR. Fluorescent intensity of at
least 10 cells per frame was measured using ImageJ Soft-
ware. MQAE florescence is inhibited in the presence of
chloride ions via diffusion-limited collisional quenching. In
chloride-rich medium, net flow of chloride ions will be into
the cell quenching MQAE signal; in chloride-deficient me-
dium (NO3
- ), net flow of chloride ions is out of the cell,
causing an increase in MQAE fluorescence.
Three-dimensional lung culture
To produce branching cell clusters, NKX2.1/FOXP2 cells
were dissociated using cell dissociation buffer and trans-
ferred to cold Matrigel. Matrigel was prepared according
to the manufacturer’s recommendations and supplemented
with FGF10 (100 ng/mL). Dissociated cells were washed
and then mixed with Matrigel. Fifty microliter of matrigel
and cells were then blotted onto wells of a pre-warmed
24-well plate to produce solid spheres of Matrigel and cells.
Medium containing FGF10 was then added. To produce
cystic distal airway three-dimensional (3D) cultures, NKX2
.1/SFTPC-positive cells were dissociated and mounted in
Matrigel containing FGF10 as described earlier.
Results
FGF10 and RA generate NKX2.1 + , FOXP2 + ,
and HHEX - lung progenitor cells
Our overall objective was to develop a methodology for
differentiation of hFSCs into RECs. To achieve this, we first
focused on the differentiation of hFSCs into cells corre-
sponding to the lung bud. We have previously demonstrated
the capacity of hFSCs to spontaneously differentiate into lung
and/or thyroid progenitors [6]. Indeed, when injected under
the kidney capsule of immunodeficient mice, hFSCs form
cystic structures containing cells expressing the lung/thyroid
marker NKX2.1 [6]. However, little is known about the sig-
naling cascades controlling lung specification in the foregut.
FGF10 is considered the key pathway involved [14,15]. RA is
also implicated in early lung development, as disruption of
RA signaling in mice leads to poorly developed lungs and the
use of RA receptor antagonists prevents foregut explant
cultures from developing the lung primordium [16].
To generate early lung progenitors in vitro from hFSCs,
we decided to study the effect of multiple growth factors
known to direct lung specification, including FGF10 and RA
[14,15,17]. We first treated hFSCs with a combination of
FGF2, FGF4, and FGF10 (Fig. 1A, B) and found that all
three FGFs are sufficient to induce expression of lung bud
markers NKX2.1, GATA6, IRX1, and FOXA2 at levels
similar to those of human FL (Fig. 1B and data not shown).
However, in contrast to FGF10, FGF2 induced HHEX and
PAX8 mRNA expression along with NKX2.1, suggesting
that this pathway could promote hFSCs differentiation into a
thyroid-like cell population (Fig. 1B, C; Supplementary Fig.
S1A). Analyses of other signaling pathways such as trans-
forming growth factor (TGF)b revealed that they did not
play a significant role in inducing the pulmonary endoderm
phenotype (Supplementary Fig. S1A, B). Considered to-
gether, these results demonstrate that FGF signaling is suf-
ficient and necessary for specification of hFSCs into lung
and thyroid progenitors with FGF2 inducing thyroid markers
and FGF10 more specific for lung markers.
Although all FGFs were able to induce NKX2.1, none
were able to induce coexpression of the lung bud marker
FOXP2. To determine whether multiple signal pathways
were required to specify the lung domain in vitro, we de-
cided to characterize the effect of combinations of growths
factors, including members of the FGF, TGF, and Wnt
pathways. RA was the only factor identified by this screen to
have a synergistic effect with FGF10. Indeed, supplemen-
tation of FGF10 with RA increased cell proliferation (data
not shown), upregulated the lung bud marker FOXP2 to
levels observed in FL (Fig. 1B), and suppressed the ex-
pression of the thyroid markers HHEX, PAX8, and PAX9
(Fig. 1B; Supplementary Fig. S1A). Coexpression of
NKX2.1 and FOXP2 was confirmed by immunostaining
(Fig. 1C), while the expression of mature lung markers such
as FOXJ1, SOX17, MUC5AC, and SFTPC (Fig. 1B; Sup-
plementary Fig. S1A) was not detected, confirming that the
resulting cells correspond to early lung progenitor cells,
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rather than mature RECs. Importantly, these progenitor cells
could not be generated in the presence of FGF10 or RA
alone, as well as RA combined with FGF2 (Fig. 1C). Col-
lectively, these results demonstrate that a combination of
FGF10 and RA is required to produce pulmonary endoderm
in vitro corresponding to the lung bud.
NKX2.1 + /FOXP2 + lung progenitors produce distal
airway epithelium similar to AECTII and AECTI cells
We next decided to characterize the capacity of the
NKX2.1 + /FOXP2 + lung progenitors to mature into a more
adult-like airway epithelium. In the mouse, the lung bud
FIG. 1. RA and FGF10 pat-
tern foregut endoderm into
NKX2.1/FOXP2-positive lung
endoderm. (A) Protocol to
produce lung endoderm pro-
genitors and distal lung
epithelium. (B) Quantitative
polymerase chain reaction
(QPCR) analysis showing
hFSCs cultured in medium
containing FGF10 with or
without additional growth
factors express early lung
progenitor genes (NKX2.1,
FOXP2, and GATA6) and do
not express more mature lung
genes (SOX17, FOXJ1) or
genes associated with thyroid
progenitors (HHEX). (C) Im-
munocytochemistry showing
hFSCs cultured in medium
containing FGF10 and RA
coexpress early lung progen-
itor genes (NKX2.1, FOXP2),
while hFSCs cultured in the
presence of FGF inhibitor
SU5402, FGF10 without RA,
or FGF2 do not express these
genes. White bars = 100 mM.
*P £ 0.05, **P £ 0.01, ***P £
0.001, ****P £ 0.0001. RA,
retinoic acid; FGF, fibroblast
growth factor; hFSCs, human
foregut stem cells; FL, human
fetal lung control; AL, adult
lung control; C, undifferenti-
ated hESC control; hESC,
human embryonic stem cell;
ns, not significant.
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branches and invades the surrounding mesenchyme in a
process largely driven by FGF10 from the surrounding
mesenchyme. The production of distal airway epithelial
cells that occurs gradually over the canalicular and saccular
stages of FL development is also dependant on a continuous
FGF signal. We therefore decided to test the effect of pro-
longed FGF10 signaling on the NKX2.1/FOXP2-positive
population. Cells cultured in medium containing FGF10 and
HGF for 10 days and then FGF10 alone for a further 15 days
continued to express markers indicative of the distal tip
airway epithelium (NKX2.1 and GATA6) and downregulated
the lung bud markers (FOXP2) (Fig. 2A), suggesting that
cells were adopting a more distal REC fate. Indeed, FGF10
exposure induced expression of several mature lung epi-
thelium markers, predominantly characteristic of AECTII
(ABCA3, CFTR, MUC1, SFTPB, and SFTPC) and AECTI
(AQP5, PDPN and P2X7) (Fig. 2A and data not shown) in
the absence of markers of other lineages such as the fore-
brain (PAX6) or the thyroid (HHEX, PAX8, PAX9, and TG;
Supplementary Fig. S2A). Coexpression of NKX2.1 and the
AECTII marker Pro-SFTPC; Pro-SFTPC and the epithelial
marker CK18; as well as a cell surface marker CD26 and
CFTR was further confirmed by immunostaining (Fig. 2B;
Supplementary Fig. S2B). Of note, CFTR is expressed in a
variety of endodermal cell types, including cells of the
intestines and pancreas; however, co-immunocytochem-
istry of the CFTR with PDX1 (Pancreas) or CDX2 (in-
testine) revealed cells that were negative for these lineage
markers and instead expressed high levels of the distal
airway marker NKX2.1 (Supplementary Fig. S2D). Flow
cytometric analyses revealed that 80% of cells expressed
NKX2.1 and CFTR, and 70% expressed Pro-SFTPC (Fig.
2C). Importantly, the resulting cells did not exhibit sig-
nificant expression of secretory cell markers (MUC5AC)
or markers of ciliated cells (FOXJ1, SOX17), suggesting
that FGF10 supports development of more distal lineages
rather than proximal airway cell types (Supplementary
Fig. S2A).
In vivo, distal AECs are organized in 3D alveolar struc-
tures, exhibiting apico-basal polarity. The capacity of our
system for the generation-polarized epithelial cells in two-
dimensional culture was demonstrated by confocal micros-
copy, which confirmed apical localization of CFTR and
CD26 and lateral localization of the tight junction marker
ZO1 as expected (Supplementary Fig. S2B, C). Finally, 3D
culture resulted in the formation of lung organoids that re-
tained both their gene expression profile and functional
characteristics, demonstrating the potential of our platform
as a system for studying 3D lung morphogenesis and dis-
orders affecting distal airway formation (Supplementary
Fig. S3A–E). Considered collectively, these results under-
line the capacity of NKX2.1/FOXP2-positive cells for dif-
ferentiation into distal AECTII, AECTI, and AEC organoids
under continued FGF10 stimulation.
hFSCs-derived AECs show airway
functionality in-vitro
The airway epithelium we generated expresses two im-
portant functional genes, surfactant protein C (SFPTC) and
the ABCA3 protein, a major component of the lamellar
bodies that allow secretion of surfactant proteins. To de-
termine whether hFSCs-derived AECTII were indeed
functional, we performed an enzyme-linked immunosorbent
assay for SFPTC and found that after 24 h of culture SFTPC
could be detected in the tissue culture medium (Fig. 2D). To
assess the functionality of CFTR usually expressed in
AECTII and AECTI cells, cells were loaded with a chloride-
sensitive indicator dye (MQAE). Chloride transport across
the cell membrane in AECs relies largely on CFTR.
Fluorescence microscopy revealed that intracellular chloride
levels increased in response to a chloride-rich medium and
decreased in response to a chloride-deficient medium,
thereby confirming CFTR functionality. Importantly, using
a CFTR inhibitor, we demonstrated that this chloride influx
and efflux was indeed CFTR dependant (Fig. 2E). Con-
sidered together, these observations illustrate that distal
AECs derived from hFSCs recapitulate key functional
characteristics of their in vivo counterparts.
hIPSCs from CFTR mutant fibroblasts
form distal AECs
Despite significant progress modeling diseases in other
organs [18,19], few stem cell platforms are specifically
aimed at disease modeling in the lung. To validate the
clinical application of our culture system, we decided to
model CF, one of the most common genetic disorders in the
world, affecting as many as 1:2,000 births in Europe, with
lung transplantation remaining the only effective treatment
[20–22]. CF is caused by mutations in the CFTR, which
result in deregulation of chloride and water transport across
the lung epithelium, manifesting as an increase in airway
mucus viscosity. This causes poor mucus and pathogen
clearance, leading to inflammatory changes in the lung pa-
renchyma, fibrosis, and reduced pulmonary function [23].
The Df508 constitutes the most common mutation in CF.
Skin fibroblasts obtained from a patient carrying the CFTR
Df508 mutation were reprogrammed into hIPSCs using non-
integrative Sendai virus expressing the four factors Oct-4,
Sox2, C-Myc, and KLF-4 [24]. The resulting CF-hIPSC
lines were characterized for their pluripotent state, capacity
of differentiation into the three germ layers, and absence of
transgene integration as previously described (Supplemen-
tary Fig. S4A and data not shown) [19]. CF-hIPSCs were
then differentiated into distal AECs as described earlier
(Fig. 3A–D; Supplementary Fig. S4B, C), and the func-
tionality of the CFTR protein in the resulting cells was
tested using the MQAE assay. As expected, CF-derived lung
cells did not show a change in fluorescence, indicating their
CFTR was not functional (Fig. 3E). Interestingly, the Df508
mutation causes a temperature-sensitive mis-folding of the
CFTR whereby the activity of the Df508-CFTR has been
shown to be normal at *28C with mis-folding at 37C
[25–27]. Accordingly, the MQAE assay showed a change in
fluorescence in CF-hFSCs-derived AECs grown at 28C for
6 h before the MQAE assay, demonstrating that the func-
tionality of CFTR could be restored by a reduction in
temperature (Fig. 3E). Taken together, these data demon-
strate that our culture system enables the production of lung
epithelial cells that recapitulate the basic biology of the
Df508 mutation in vitro.
Finally, to characterize the potential of our system as a
platform for validating novel therapeutic agents, we decided
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FIG. 2. NKX2.1/FOXP2-positive lung progenitors mature into distal AEC. (A) QPCR analysis showing NKX2.1 + /
FOXP2 + -positive lung progenitor cells cultured for a further 25 days downregulate lung bud markers (FOXP2) and express
genes of the distal airway epithelium (NKX2.1, GATA6), AECTII (SFTPC, SFTPB, ABCA3, and P2X7), and AECTI
(AQP5). (B) Immunocytochemistry showing matured lung endoderm coexpressing distal airway markers (Pro-SFPTC,
CK18, and NKX2.1). (C) Flow cytometric analysis showing percentages of cells positive for distal airways markers (CFTR,
NKX2.1, and Pro-SFTPC). Red shading = positive stained Gray shading = isotype/secondary control. (D) SFTPC enzyme-
linked immunosorbent assay detection of SFTPC in tissue culture medium from cultures of matured distal airway epi-
thelium. (E) Fluorescent trace of Cl - indicator dye (MQAE) showing CFTR activity in matured airway epithelium. No
fluorescent signal was detected within lung epithelium using Cl - containing medium (t = 0 s), CFTR activity was shown by
an increase in cell fluorescence in medium containing NO3
- (t = 15 s) and then a loss of fluorescence when Cl - medium was
added back to cells (t=115 s). Cells treated with NO3- medium and a CFTR inhibitor showed no increase in fluorescence inside
lung epithelial cells (t=230 s).White bars=100mM. *P£0.05, ***P£0.001, ****P£0.0001. AEC, alveolar epithelial cell; CFTR,
cystic fibrosis transmembrane conductance regulator; FL, human foetal lung control; AL, adult lung control; C, undifferentiated
hESC control; D25, airway epithelium cultured for 25 days; MQAE, N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromine.
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FIG. 3. CFTR-Df508-derived hFSCs can differentiate into lung epithelium. (A) QPCR analysis showing that hFSCs
derived from patients with the CFTR mutation Df508 can differentiate into early lung endoderm and express early markers
(NKX2.1, FOXP2, GATA6, and FOXA2) while they are negative for more mature markers (FOXJ1, SOX2, and SOX17) and
thyroid markers (HHEX). (B) QPCR analysis showing that CFTR mutant lung progenitors can develop into mature airway
epithelium and continue to express distal airway markers (NKX2.1, GATA6) as well as AECTII markers (SFTPB, SFTPC,
and ABCA3) and AECTI markers (AQP5, P2X7, and PDPN). (C) Immunocytochemistry showing distal airway epithelium
expresses NKX2.1, SFTPC, and CK18. (D) Confocal microscopy showing localization of Pro-SFTPC in the cytoplasm of the
distal airway epithelium. (E) Trace of chloride influx and efflux in mature airway epithelium from CFTR-human-induced
pluripotent stem cell showing the temperature sensitivity of CFTR. Chloride influx and efflux was measured in mature airway
epithelium expressing the wild-type CFTR (green trace) cultured at 37C, the Df508 mutation (red trace) cultured at 37C,
and the Df508 mutation (blue trace) cultured at 28C. Addition of Cl- or NO3- indicated with solid arrowheads. White
bars= 100mM. *P£ 0.05, **P£ 0.01, ***P£ 0.001, ****P£ 0.0001. FL, human fetal lung control; AL, adult lung control; C,
undifferentiated hESC control; Df508, airway epithelium from cystic fibrosis patients cultured for 25 days.
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to assess the efficiency of the small molecule VX809 for
restoring CFTR function in CF-hFSCs-derived AECs. In-
deed, VX809 has been shown in several studies to correct
folding defects in the mature CFTR protein allowing re-
duced degradation, increased trafficking to the cell surface,
and restoration of chloride transport. CF-hFSCs-derived
lung cells were incubated for 48 h with or without VX809
and then loaded with MQAE for detection of chloride
transport. CF-hFSCs-derived AECs grown in the presence of
VX809 showed a dramatic improvement in the capacity to
transport chloride, confirming the efficiency of this drug to
correct CF in vitro (Fig. 4A). Furthermore, confocal mi-
croscopy revealed that CFTR was able to accumulate to
greater levels on VX809 treatment (Fig. 4B). Taken to-
gether, these data confirm the mode of action of VX809 and
thus demonstrate that hFSCs-derived distal AECs could be
used to predict the activity of small molecules to correct
lung diseases in vitro.
Discussion
Here, we describe the development of a novel platform
for the differentiation of hFSCs into functional distal AECs
recapitulating key stages of lung development and provide a
new system to model pulmonary diseases in vitro. Our ob-
servations expand on previous studies illustrating the dif-
ferentiation capacity of hFSC toward liver and pancreatic
lineages and underline their potential for generating cell
types from the most anterior part of the foregut such as the
thyroid and lung.
Remarkably, our protocol allows the production of a
population of lung cells expressing mainly AECTII and
AECTI markers (80% NKX2.1/CFTR/Pro-SFTPC). This
bias toward distal lung cells is not specific to hFSCs since
previous reports describe similar results with direct differ-
entiation of hPSCs when using a combination of RA and
FGF10 [3,4]. The use of BMP4 at an early stage of differ-
entiation could favor proximal lung cell production [4];
however, further studies are required to understand the
mechanisms involved in the proximo-distal patterning of the
lung progenitors in vitro and hFSCs could facilitate such
analyses, as they represent the closest embryonic stage to
lung bud induction in humans.
Indeed, we have already used hFSCs to identify key
signaling pathways controlling pulmonary differentiation.
Importantly, the function of FGF10 and RA in inducing lung
progenitor differentiation is in agreement with in vivo
studies [11,14,28] and this similarity reinforces the appli-
cation of hFSCs as a model to study early stages of lung
specification.
Importantly, the use of hFSCs versus hPSCs provides
significant advantages in terms of clinical applications.
The clinical significance of hFSCs-derived RECs was
demonstrated by modeling CF in vitro and by validating
the effects of VX809 on rescuing the disease phenotype.
Similar results have been reported with existing platforms
[4]; however, in contrast to hPSC-based systems, hFSCs-
derived AECs can be produced from any hIPSC line, even
those resistant to endoderm differentiation [6]. This im-
provement could facilitate the generation of large cohorts
of patient-specific AECs, which are required for the study
of polygenic or multifactorial disorders in vitro. Further-
more, hFSCs limit variability between experiments since
they bypass the need for endoderm differentiation, which
can be extremely variable between experiments and dif-
ferent hIPSC lines. Similarly, the generation of AECs
FIG. 4. The CFTR-Df508
mis-folded receptor can be
rescued to a functional state
using the small molecule
VX809. (A) Chloride influx
and efflux trace in mature
airway epithelial cells ex-
pressing the wild-type CFTR
(red trace), the DF508 muta-
tion in the CFTR (blue trace),
or the DF508 mutation in the
CFTR but treated with the
small molecule VX809 (green
trace). (B) Confocal micro-
scopy showing expression of
CFTR in matured airway ep-
ithelium from wild-type cells,
cells with the DF508 mutation
in the CFTR, and cells with
the DF508 mutation in the
CFTR but treated with the
small molecule VX809.White
bars= 100mM. Addition of
Cl- or NO3
- indicated with
solid arrowheads.
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from hFSCs is more time and cost effective when com-
pared with direct differentiation of hPSCs and, thus, rep-
resents a significant benefit for large-scale applications
such as drug screening.
In conclusion, our results demonstrate that hFSCs-derived
AECs can be used to study human early lung development,
drug screening, and disease modeling. More importantly,
this system represents an important technological advance
that is capable of bridging the gap between isolated proof-
of-principle studies and the large-scale clinical applications
required to fully exploit the translational potential of stem-
cell-derived AECs.
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